Mylan Return on Investment 2006-2019 | MYL

Current and historical return on investment (ROI) values for Mylan (MYL) over the last 10 years.
Mylan ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2019-03-31 $0.77B $26.11B 2.93%
2018-12-31 $0.91B $26.43B 3.41%
2018-09-30 $1.09B $26.51B 4.07%
2018-06-30 $1.07B $26.58B 3.97%
2018-03-31 $1.37B $26.76B 4.98%
2017-12-31 $1.44B $27.41B 5.20%
2017-09-30 $1.33B $27.28B 4.80%
2017-06-30 $0.88B $28.23B 3.26%
2017-03-31 $0.82B $27.73B 3.18%
2016-12-31 $0.70B $27.68B 2.99%
2016-09-30 $0.81B $24.80B 3.96%
2016-06-30 $1.54B $23.10B 8.32%
2016-03-31 $1.41B $17.94B 8.30%
2015-12-31 $1.46B $16.06B 8.84%
2015-09-30 $1.43B $17.02B 9.47%
2015-06-30 $1.32B $16.84B 9.85%
2015-03-31 $1.27B $16.22B 10.28%
2014-12-31 $1.35B $10.31B 11.89%
2014-09-30 $1.23B $10.40B 10.49%
2014-06-30 $1.08B $12.57B 9.24%
2014-03-31 $1.16B $12.24B 10.63%
2013-12-31 $1.14B $11.82B 11.14%
2013-09-30 $1.13B $10.04B 11.72%
2013-06-30 $1.12B $9.61B 12.04%
2013-03-31 $1.07B $9.34B 11.80%
2012-12-31 $1.11B $9.46B 12.29%
2012-09-30 $1.09B $8.83B 12.37%
2012-06-30 $1.03B $8.75B 11.76%
2012-03-31 $1.04B $9.07B 11.87%
2011-12-31 $1.01B $8.73B 11.44%
2011-09-30 $0.85B $8.32B 9.56%
2011-06-30 $0.82B $9.06B 8.97%
2011-03-31 $0.74B $9.04B 8.17%
2010-12-31 $0.72B $9.25B 8.10%
2010-09-30 $0.69B $9.22B 7.85%
2010-06-30 $0.52B $8.49B 5.98%
2010-03-31 $0.50B $8.72B 5.78%
2009-12-31 $0.52B $8.62B 6.24%
2009-09-30 $0.50B $8.61B 6.00%
2009-06-30 $1.00B $8.30B 12.08%
2009-03-31 $0.90B $8.02B 10.93%
2008-12-31 $0.30B $8.29B 3.62%
2008-09-30 $-1.00B $8.44B -12.10%
2008-06-30 $-1.47B $8.08B -20.92%
2008-03-31 $-1.35B $8.13B -23.14%
2007-12-31 $-0.99B $8.32B -21.28%
2007-09-30 $0.67B $3.50B 22.35%
2007-06-30 $0.72B $3.42B 28.03%
2007-03-31 $0.65B $3.33B 30.79%
2006-12-31 $0.65B $1.81B 39.93%
2006-09-30 $0.56B $1.67B 35.79%
2006-06-30 $0.49B $1.58B 31.11%
2006-03-31 $0.43B $1.50B 26.13%
2005-12-31 $0.43B $1.55B 24.73%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $8.773B $11.434B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $37.999B 6.92
Teva Pharmaceutical Industries (TEVA) Israel $8.379B 3.28
Bausch Health Cos (BHC) Canada $7.555B 5.16
Dr Reddy's Laboratories (RDY) India $6.155B 23.02
Supernus Pharmaceuticals (SUPN) United States $1.645B 16.44
Amphastar Pharmaceuticals (AMPH) United States $0.933B 52.16
Voyager Therapeutics (VYGR) United States $0.893B 0.00
Homology Medicines (FIXX) United States $0.809B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.778B 1.16
Akorn (AKRX) United States $0.535B 0.00
CymaBay Therapeutics (CBAY) United States $0.431B 0.00
Assembly Biosciences (ASMB) United States $0.371B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.347B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.275B 0.00
Sol-Gel Technologies (SLGL) Israel $0.161B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.125B 0.00
Acasti Pharma (ACST) Canada $0.071B 0.00
Agile Therapeutics (AGRX) United States $0.058B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.054B 0.00
Teligent (TLGT) United States $0.030B 0.00
Evoke Pharma (EVOK) United States $0.015B 0.00
Aevi Genomic Medicine (GNMX) United States $0.011B 0.00